Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

LAWRENCE DAVID GINSBERG

Allopathic & Osteopathic Physicians Psychiatry & Neurology Psychiatry

NPI
1851385835
CMS profile
128918
Location
HOUSTON, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$109,656.64

373 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

By paying entity

PY2023 · entire year · sorted by reported total

Page 2 of 8; records 51–100 of 373 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

LAWRENCE DAVID GINSBERG

NPI 1851385835 · CMS profile ID 128918

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Psychiatry

HOUSTON, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 8; records 51–100 of 373 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1851385835?year=2023&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
LAWRENCE DAVID GINSBERG, NPI 1851385835, CMS profile ID 128918. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 8; records 51–100 of 373 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1851385835?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). LAWRENCE DAVID GINSBERG, NPI 1851385835, CMS profile ID 128918. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 8; records 51–100 of 373 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1851385835?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
LAWRENCE DAVID GINSBERG, NPI 1851385835, CMS profile ID 128918, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 8; records 51–100 of 373 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1851385835?year=2023&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

373 matching records · $109,656.64 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 373 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 373.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Otsuka America Pharmaceutical, Inc. $12.6410/20/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014361028 CMS
IDORSIA PHARMACEUTICALS US INC $122.5210/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1038288393 CMS
Otsuka America Pharmaceutical, Inc. $15.7710/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014361015 CMS
Otsuka America Pharmaceutical, Inc. $0.9310/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014361023 CMS
Supernus Pharmaceuticals, Inc. $7.5410/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053249975 CMS
Alkermes, Inc. $2,750.0010/17/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1022823039 CMS
ABBVIE INC. $5.4410/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997346231 CMS
Teva Pharmaceuticals USA, Inc. $23.2010/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056730821 CMS
ABBVIE INC. $2,500.0010/13/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997346229 CMS
Alkermes, Inc. $2,050.0010/10/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1022823037 CMS
Vanda Pharmaceuticals Inc. $14.6510/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1051525621 CMS
Axsome Therapeutics, Inc. $22.7710/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056178969 CMS
ABBVIE INC. $7.4710/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997346227 CMS
Alkermes, Inc. $17.3110/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1022823035 CMS
Axsome Therapeutics, Inc. $12.2210/04/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056179005 CMS
Otsuka America Pharmaceutical, Inc. $2,808.0010/04/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014361007 CMS
Alkermes, Inc. $4.0010/03/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1022823027 CMS
Alkermes, Inc. $155.9810/03/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1022823029 CMS
Alkermes, Inc. $31.4410/03/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1022823031 CMS
Alkermes, Inc. $79.9510/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1022823033 CMS
Validus Pharmaceuticals LLC $12.7910/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991141825 CMS
ABBVIE INC. $7.0010/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997346225 CMS
ITI, Inc. $17.6209/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040539139 CMS
Almatica Pharma LLC $15.8409/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 993446213 CMS
Otsuka America Pharmaceutical, Inc. $121.8609/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014360999 CMS
Alkermes, Inc. $26.9209/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1022823025 CMS
ABBVIE INC. $6.9309/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997346223 CMS
ABBVIE INC. $2.5009/20/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997346215 CMS
ABBVIE INC. $15.8509/20/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997346217 CMS
ABBVIE INC. $105.6409/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997346219 CMS
ABBVIE INC. $3.0009/20/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997346221 CMS
Neurocrine Biosciences, Inc. $25.0709/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1052029779 CMS
ABBVIE INC. $4.6109/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997346213 CMS
Almatica Pharma LLC $6.3709/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 993446211 CMS
Ironshore Pharmaceuticals Inc. $16.5009/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1060478219 CMS
Tris Pharma Inc $7.0009/18/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059325231 CMS
Tris Pharma Inc $17.1609/18/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059325233 CMS
Alkermes, Inc. $1.5009/14/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1022823019 CMS
Alkermes, Inc. $5.3409/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1022823021 CMS
Alkermes, Inc. $69.4309/14/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1022823023 CMS
Alkermes, Inc. $2,175.0009/13/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1022823015 CMS
Alkermes, Inc. $2,175.0009/13/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1022823017 CMS
Otsuka America Pharmaceutical, Inc. $19.0509/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014360991 CMS
ABBVIE INC. $6.1109/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997346211 CMS
Teva Pharmaceuticals USA, Inc. $25.5509/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056730787 CMS
Tris Pharma Inc $3,800.0009/11/2023 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059325229 CMS
Alkermes, Inc. $4.5209/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1022823013 CMS
Alkermes, Inc. $16.8409/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1022823011 CMS
ABBVIE INC. $17.0109/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997346209 CMS
Almatica Pharma LLC $17.4508/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 993446209 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $60,047.06 300
PY2020 $35,727.23 244
PY2021 $85,697.85 329
PY2022 $98,507.79 360
PY2023 $109,656.64 373
PY2024 $68,862.18 328
PY2025 $43,175.14 271

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $113,074.86 62
PY2024 Recipient $8,339.70 1
PY2024 Principal investigator $171,544.61 25
PY2023 Recipient $41,466.30 2
PY2023 Principal investigator $223,667.03 25
PY2022 Recipient $137,051.35 13
PY2022 Principal investigator $54,095.31 25
PY2021 Recipient $162,977.20 16
PY2021 Principal investigator $146,978.97 28
PY2020 Recipient $29,400.50 12
PY2020 Principal investigator $554,360.17 82
PY2019 Recipient $4,351.83 14
PY2019 Principal investigator $672,338.83 65

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

62 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $1,699.68 12/31/2025 Non-covered Recipient Entity
RED OAK PSYCHIATRY ASSOCIATES
A 52-Week, Multicenter, Open-Label, Flexible-dose Study to Evaluate the Long-term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Subjects with Schizophrenia, Bipolar I Disorder, or Autism Spectrum Disorder No dispute reported 06/30/2026 1202534447
Principal investigator 1 ABBVIE INC. $183.28 12/31/2025 Non-covered Recipient Entity
RED OAK PSYCHIATRY ASSOCIATES
A 6-week, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Efficacy and Safety of Cariprazine in Pediatric Subjects (10 to 17 years of age) in the Treatment of Depressive Episodes Associated with Bipolar I Disorder No dispute reported 06/30/2026 1202534449
Principal investigator 1 Boehringer Ingelheim International GmbH $914.00 11/25/2025 Non-covered Recipient Entity
Red Oak Psychiatry Associates PA
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220774083
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 11/25/2025 Non-covered Recipient Entity
Red Oak Psychiatry Associates PA
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220774085
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 11/25/2025 Non-covered Recipient Entity
Red Oak Psychiatry Associates PA
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220774087
Principal investigator 1 Boehringer Ingelheim International GmbH $954.00 11/25/2025 Non-covered Recipient Entity
Red Oak Psychiatry Associates PA
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220774089
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 11/25/2025 Non-covered Recipient Entity
Red Oak Psychiatry Associates PA
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220774091
Principal investigator 1 Boehringer Ingelheim International GmbH $200.00 11/25/2025 Non-covered Recipient Entity
Red Oak Psychiatry Associates PA
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220774093
Principal investigator 1 Boehringer Ingelheim International GmbH $914.00 11/25/2025 Non-covered Recipient Entity
Red Oak Psychiatry Associates PA
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220774095
Principal investigator 1 Boehringer Ingelheim International GmbH $954.00 11/25/2025 Non-covered Recipient Entity
Red Oak Psychiatry Associates PA
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220774097
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 11/25/2025 Non-covered Recipient Entity
Red Oak Psychiatry Associates PA
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220774099
Principal investigator 1 Boehringer Ingelheim International GmbH $200.00 11/25/2025 Non-covered Recipient Entity
Red Oak Psychiatry Associates PA
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220774101
Principal investigator 1 Boehringer Ingelheim International GmbH $954.00 11/25/2025 Non-covered Recipient Entity
Red Oak Psychiatry Associates PA
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220774103
Principal investigator 1 Boehringer Ingelheim International GmbH $914.00 11/25/2025 Non-covered Recipient Entity
Red Oak Psychiatry Associates PA
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220774105
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 10/02/2025 Non-covered Recipient Entity
Red Oak Psychiatry Associates PA
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220774075
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 10/02/2025 Non-covered Recipient Entity
Red Oak Psychiatry Associates PA
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220774077
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 10/02/2025 Non-covered Recipient Entity
Red Oak Psychiatry Associates PA
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220774079
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 10/02/2025 Non-covered Recipient Entity
Red Oak Psychiatry Associates PA
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220774081
Principal investigator 1 Boehringer Ingelheim International GmbH $954.00 08/22/2025 Non-covered Recipient Entity
Red Oak Psychiatry Associates PA
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220774067
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 08/22/2025 Non-covered Recipient Entity
Red Oak Psychiatry Associates PA
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220774069
Principal investigator 1 Boehringer Ingelheim International GmbH $954.00 08/22/2025 Non-covered Recipient Entity
Red Oak Psychiatry Associates PA
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220774071
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 08/22/2025 Non-covered Recipient Entity
Red Oak Psychiatry Associates PA
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220774073
Principal investigator 1 ACADIA Pharmaceuticals Inc $820.63 08/18/2025 Non-covered Recipient Entity
RED OAK PSYCHIATRY ASSOCIATES
ACP-103-070 No dispute reported 06/30/2026 1245935533
Principal investigator 1 Boehringer Ingelheim International GmbH $914.00 07/28/2025 Non-covered Recipient Entity
Red Oak Psychiatry Associates PA
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220774063
Principal investigator 1 Boehringer Ingelheim International GmbH $538.00 07/28/2025 Non-covered Recipient Entity
Red Oak Psychiatry Associates PA
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220774065
Principal investigator 1 Boehringer Ingelheim International GmbH $1,511.00 06/25/2025 Non-covered Recipient Entity
Red Oak Psychiatry Associates PA
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220774049
Principal investigator 1 Boehringer Ingelheim International GmbH $538.00 06/25/2025 Non-covered Recipient Entity
Red Oak Psychiatry Associates PA
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220774051
Principal investigator 1 Boehringer Ingelheim International GmbH $914.00 06/25/2025 Non-covered Recipient Entity
Red Oak Psychiatry Associates PA
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220774053
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 06/25/2025 Non-covered Recipient Entity
Red Oak Psychiatry Associates PA
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220774055
Principal investigator 1 Boehringer Ingelheim International GmbH $914.00 06/25/2025 Non-covered Recipient Entity
Red Oak Psychiatry Associates PA
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220774057
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 06/25/2025 Non-covered Recipient Entity
Red Oak Psychiatry Associates PA
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220774059
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 06/25/2025 Non-covered Recipient Entity
Red Oak Psychiatry Associates PA
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220774061
Principal investigator 1 Boehringer Ingelheim International GmbH $1,511.00 05/27/2025 Non-covered Recipient Entity
Red Oak Psychiatry Associates PA
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220774041
Principal investigator 1 Boehringer Ingelheim International GmbH $1,511.00 05/27/2025 Non-covered Recipient Entity
Red Oak Psychiatry Associates PA
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220774043
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 05/27/2025 Non-covered Recipient Entity
Red Oak Psychiatry Associates PA
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220774045
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 05/27/2025 Non-covered Recipient Entity
Red Oak Psychiatry Associates PA
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220774047
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $1,158.00 05/21/2025 Non-covered Recipient Entity
RED OAK PSYCHIATRY ASSOCIATES PA
ITI-007-321 No dispute reported 06/30/2026 1242347650
Principal investigator 1 ACADIA Pharmaceuticals Inc $1,798.81 05/12/2025 Non-covered Recipient Entity
RED OAK PSYCHIATRY ASSOCIATES
ACP-103-069 No dispute reported 06/30/2026 1245934223
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $81.00 05/07/2025 Non-covered Recipient Entity
RED OAK PSYCHIATRY ASSOCIATES PA
ITI-007-421 No dispute reported 06/30/2026 1242347316
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $7,000.00 05/02/2025 Non-covered Recipient Entity
RED OAK PSYCHIATRY ASSOCIATES PA
ITI-007-602 No dispute reported 06/30/2026 1242345681
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $6,099.00 04/23/2025 Non-covered Recipient Entity
RED OAK PSYCHIATRY ASSOCIATES PA
ITI-007-321 No dispute reported 06/30/2026 1242344003
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $5,246.00 04/04/2025 Non-covered Recipient Entity
RED OAK PSYCHIATRY ASSOCIATES PA
ITI-007-421 No dispute reported 06/30/2026 1242339620
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $4,822.00 04/04/2025 Non-covered Recipient Entity
RED OAK PSYCHIATRY ASSOCIATES PA
ITI-007-421 No dispute reported 06/30/2026 1242339622
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $6,167.00 04/02/2025 Non-covered Recipient Entity
RED OAK PSYCHIATRY ASSOCIATES PA
ITI-007-321 No dispute reported 06/30/2026 1242339085
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $5,246.00 03/10/2025 Non-covered Recipient Entity
RED OAK PSYCHIATRY ASSOCIATES PA
ITI-007-421 No dispute reported 06/30/2026 1242334860
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $81.00 03/10/2025 Non-covered Recipient Entity
RED OAK PSYCHIATRY ASSOCIATES PA
ITI-007-421 No dispute reported 06/30/2026 1242334862
Principal investigator 1 ABBVIE INC. $1,427.00 03/06/2025 Non-covered Recipient Entity
RED OAK PSYCHIATRY ASSOCIATES PA
Open-Label Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1202456651
Principal investigator 1 ACADIA Pharmaceuticals Inc $4,418.70 03/03/2025 Non-covered Recipient Entity
RED OAK PSYCHIATRY ASSOCIATES
ACP-103-069 No dispute reported 06/30/2026 1245933699
Principal investigator 1 ACADIA Pharmaceuticals Inc $69.21 03/03/2025 Non-covered Recipient Entity
RED OAK PSYCHIATRY ASSOCIATES
ACP-103-069 No dispute reported 06/30/2026 1245933701
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $4,487.00 02/25/2025 Non-covered Recipient Entity
RED OAK PSYCHIATRY ASSOCIATES PA
ITI-007-321 No dispute reported 06/30/2026 1242333028
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $6,032.00 02/25/2025 Non-covered Recipient Entity
RED OAK PSYCHIATRY ASSOCIATES PA
ITI-007-321 No dispute reported 06/30/2026 1242333030
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $5,219.00 02/25/2025 Non-covered Recipient Entity
RED OAK PSYCHIATRY ASSOCIATES PA
ITI-007-321 No dispute reported 06/30/2026 1242333032
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $5,095.00 02/25/2025 Non-covered Recipient Entity
RED OAK PSYCHIATRY ASSOCIATES PA
ITI-007-321 No dispute reported 06/30/2026 1242333074
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $5,219.00 02/25/2025 Non-covered Recipient Entity
RED OAK PSYCHIATRY ASSOCIATES PA
ITI-007-321 No dispute reported 06/30/2026 1242333076
Principal investigator 1 Boehringer Ingelheim International GmbH $264.55 01/21/2025 Non-covered Recipient Entity
Red Oak Psychiatry Associates PA
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220774107
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $4,957.00 01/13/2025 Non-covered Recipient Entity
RED OAK PSYCHIATRY ASSOCIATES PA
ITI-007-421 No dispute reported 06/30/2026 1242328594
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $81.00 01/13/2025 Non-covered Recipient Entity
RED OAK PSYCHIATRY ASSOCIATES PA
ITI-007-421 No dispute reported 06/30/2026 1242328647
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,953.00 01/13/2025 Non-covered Recipient Entity
RED OAK PSYCHIATRY ASSOCIATES PA
ITI-007-421 No dispute reported 06/30/2026 1242328649
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,581.00 01/13/2025 Non-covered Recipient Entity
RED OAK PSYCHIATRY ASSOCIATES PA
ITI-007-421 No dispute reported 06/30/2026 1242328651
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,953.00 01/13/2025 Non-covered Recipient Entity
RED OAK PSYCHIATRY ASSOCIATES PA
ITI-007-421 No dispute reported 06/30/2026 1242328653
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,953.00 01/13/2025 Non-covered Recipient Entity
RED OAK PSYCHIATRY ASSOCIATES PA
ITI-007-421 No dispute reported 06/30/2026 1242328655
Principal investigator 1 ABBVIE INC. $4,000.00 01/02/2025 Non-covered Recipient Entity
RED OAK PSYCHIATRY ASSOCIATES PA
Open-Label Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia or Bipolar I Disorder No dispute reported 06/30/2026 1202434517